Related references
Note: Only part of the references are listed.Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell
Chu Lin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Natural killer cell cytotoxicity and its regulation by inhibitory receptors
Santosh Kumar
IMMUNOLOGY (2018)
Natural killer cell specificity for viral infections
Quirin Hammer et al.
NATURE IMMUNOLOGY (2018)
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2018)
Reprogramming human T cell function and specificity with non-viral genome targeting
Theodore L. Roth et al.
NATURE (2018)
Natural killer cells and other innate lymphoid cells in cancer
Laura Chiossone et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Natural Killer Cells: Angels and Devils for Immunotherapy
Beatriz Martin-Antonio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
New development in CAR-T cell therapy
Zhenguang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Mingxue Fan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
K. H. Chen et al.
LEUKEMIA (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene
Zhang-Hui Chen et al.
NATURE BIOTECHNOLOGY (2017)
NK cell-based immunotherapy for cancer
Fang Fang et al.
SEMINARS IN IMMUNOLOGY (2017)
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Brent A. Williams et al.
ONCOTARGET (2017)
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
Congcong Zhang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Phase 1 clinical trial of adoptive immunotherapy using off-the-shelf activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
Michael Boyiadzis et al.
CYTOTHERAPY (2017)
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma
Sarah Oelsner et al.
CYTOTHERAPY (2017)
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD
Elad Jacoby et al.
BLOOD (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
Sabrina Genssler et al.
ONCOIMMUNOLOGY (2016)
Exploitation of natural killer cells for the treatment of acute leukemia
Rupert Handgretinger et al.
BLOOD (2016)
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
Annette Romanski et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival
Ryan Alkins et al.
NEURO-ONCOLOGY (2016)
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Kevin H. Chen et al.
ONCOTARGET (2016)
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
Xilin Chen et al.
ONCOTARGET (2016)
Natural Killer Cells for immunotherapy-Advantages of the NK-92 Cell Line over Blood NK Cells
Hans Klingemann et al.
FRONTIERS IN IMMUNOLOGY (2016)
Natural killer cell memory in infection, inflammation and cancer
Adelheid Cerwenka et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma
Diana Seidel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Hollie J. Pegram et al.
IMMUNOTHERAPY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Advantages and applications of CAR-expressing natural killer cells
Wolfgang Glienke et al.
FRONTIERS IN PHARMACOLOGY (2015)
Natural killer cell immunotherapy: from bench to bedside
Anna Domogala et al.
FRONTIERS IN IMMUNOLOGY (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells
Gabrielle Romain et al.
BLOOD (2014)
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells
Michael C. Jensen et al.
IMMUNOLOGICAL REVIEWS (2014)
Transfection of chimeric anti-CD 138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Hua Jiang et al.
MOLECULAR ONCOLOGY (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors
Ryan Alkins et al.
CANCER RESEARCH (2013)
A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
Yu-Hsiang Chang et al.
CANCER RESEARCH (2013)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody
Ge Zhang et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
Natural killer cell biology: An update and future directions
Kerry S. Campbell et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
Laurent Boissel et al.
ONCOIMMUNOLOGY (2013)
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
D. V. Tassev et al.
CANCER GENE THERAPY (2012)
Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
Christiane Sahm et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model
Brenna E. Swift et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
Ruth Esser et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Cancer immunotherapy: Are we there yet?
Benjamin Sredni et al.
SEMINARS IN CANCER BIOLOGY (2012)
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Markus Chmielewski et al.
CANCER RESEARCH (2011)
Depicting Adoptive Immunotherapy for Prostate Cancer in an Animal Model with Magnetic Resonance Imaging
Reinhard Meier et al.
MAGNETIC RESONANCE IN MEDICINE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-γ on activation
Andrea De Maria et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
ITAM-mediated Signaling by the T-Cell Antigen Receptor
Paul E. Love et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells
Bianca Altvater et al.
CLINICAL CANCER RESEARCH (2009)
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
Laurent Boissel et al.
LEUKEMIA RESEARCH (2009)
Optical Imaging of Cellular Immunotherapy against Prostate Cancer
Sidhartha Tavri et al.
MOLECULAR IMAGING (2009)
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
S. Arai et al.
CYTOTHERAPY (2008)
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
Liat Binyamin et al.
JOURNAL OF IMMUNOLOGY (2008)
Up on the tightrope: natural killer cell activation and inhibition
Lewis L. Lanier
NATURE IMMUNOLOGY (2008)
Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors
Reinhard Meier et al.
NUCLEAR MEDICINE AND BIOLOGY (2008)
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells
Tina Mueller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains
Jinjuan Wang et al.
HUMAN GENE THERAPY (2007)
CD56bright CD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation
Chiara Romagnani et al.
JOURNAL OF IMMUNOLOGY (2007)
Tumor and viral recognition by natural killer cells receptors
Tal I. Arnon et al.
SEMINARS IN CANCER BIOLOGY (2006)
CD28-stimulated ERK2 phosphorylation is required for polarization of the microtubule organizing center and granules in YTS NK cells
Xi Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity
G Suck et al.
EXPERIMENTAL HEMATOLOGY (2005)
2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells
ME McNerney et al.
MOLECULAR IMMUNOLOGY (2005)
Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells
KV Konstantinidis et al.
EXPERIMENTAL HEMATOLOGY (2005)
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging
HE Daldrup-Link et al.
EUROPEAN RADIOLOGY (2005)
Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells
Y Isobe et al.
CANCER RESEARCH (2004)
A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization
IM Chen et al.
LEUKEMIA RESEARCH (2004)
CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2:: a potential new link between adaptive and innate immunity
TA Fehniger et al.
BLOOD (2003)
Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy
YK Tam et al.
CYTOTHERAPY (2003)
Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity
P Le Bouteiller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation
S Gilfillan et al.
NATURE IMMUNOLOGY (2002)
The biology of human natural killer-cell subsets
MA Cooper et al.
TRENDS IN IMMUNOLOGY (2001)
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92
T Tonn et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92
G Maki et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Characterization of novel natural killer (NK)-cell and γδ T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus
H Nagata et al.
BLOOD (2001)
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation
M Yagita et al.
LEUKEMIA (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
